Indications and safety of proton pump inhibitor drug use in patients with cancer

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 659-672

  Triadafilopoulos, George ^a   Roorda, Andrew K ^b   Akiyama, Junichi ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b El Camino GI Medical Associates   (United States)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Acid peptic diseases; Cancer; Drug safety; Proton pump inhibitors

Indexed keywords

ADRENALIN; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; CELECOXIB; CLOPIDOGREL; DIDANOSINE; ERLOTINIB; ESOMEPRAZOLE; FLUOROURACIL; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; KETOROLAC; LANSOPRAZOLE; LOCAL ANESTHETIC AGENT; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; PANTOPRAZOLE; PHENYTOIN; PIROXICAM; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANALGESIA; CANCER PAIN; CANCER PATIENT; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; CYANOCOBALAMIN DEFICIENCY; DIGESTIVE SYSTEM CANCER; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; ESOPHAGITIS; ESOPHAGUS RESECTION; FRACTURE; GASTRECTOMY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGASTRINEMIA; HYPOMAGNESEMIA; INTERSTITIAL NEPHRITIS; IRON DEFICIENCY; LOWER ESOPHAGUS SPHINCTER; MAGNESIUM DEFICIENCY; META ANALYSIS; PEPTIC ULCER; RESPIRATORY TRACT INFECTION; REVIEW; STENT; STOMACH HEMORRHAGE; STOMACH PERFORATION; STOMACH ULCER; TOPICAL ANESTHESIA; NEOPLASMS;

HUMANS; NEOPLASMS; PROTON PUMP INHIBITORS;

EID: 84897351402     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.797961     Document Type: Review

References (109)

1. Shin JM, Sachs G. Long lasting inhibitors of the gastric H, K-ATPase. Expert Rev Clin Pharmacol 2009;2:461-8
2. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitors versus H2- antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001;15:917-26
3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200
4. Arora G, Singh G, Triadafilopoulos G. Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clin Gastroenterol Hepatol 2009;7:725-35
5. Gisbert JP, Khorrami S, Calvet X, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:757-66
6. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs 2008;68:925-47
7. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003;18:559-68
8. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-92
9. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41
10. Aly A, Jamieson GG. Reflux after oesophagectomy. Br J Surg 2004;91:137-41
11. De Boer AG, Genovesi PI, Sprangers MA, et al. Quality of life in long-term survivors after curative transhiatal oesophagectomy for oesophageal carcinoma. Br J Surg 2000;87:1716-21
12. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005;CD005180
13. Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients. Aliment Pharmacol Ther 2010;32:1240-8
14. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38
15. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46
16. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-44
17. Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology 1983;85:346-50
18. Leontiadis GI, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal bleeding. Gastroenterol Clin North Am 2009;38:199-213
19. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345-60
20. Wishingrad M, Kim M, Triadafilopoulos G. Early dysphagia after placement of a self-expanding esophageal stent: severe esophagitis mimicking luminal occlusion. Am J Gastroenterol 1995;90:1525-6
21. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40
22. Wilcox CM, Seay T, Arcury JT, et al. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis 2011;43:439-43
23. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade Bcell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7
24. Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute, Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-413
25. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931-50
26. Festen HP. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl 1991;188:1-7
27. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 1992;6:399-406
28. Schenk BE, Festen HP, Kuipers EJ, et al. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996;10:541-5
29. Bellou A, Aimone-Gastin I, De Korwin JD, et al. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J Intern Med 1996;240:161-4
30. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422-8
31. den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008;27:491-7
32. Bezwoda W, Charlton R, Bothwell T, et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med 1978;92:108-16
33. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009;104(Suppl 2):S5-9 . A review paper showing various effects of proton pump inhibitors on vitamine C, vitamin B12, and iron.
34. Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36(5):405-13
35. Sierra F, Suarez M, Rey M, et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007;26(4):545-53
36. Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol 1995;26:1413-18
37. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002;30:1118-22
38. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008;22:761-6
39. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31:627-36
40. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003;18:847-51
41. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-80
42. Gau JT, Acharya U, Khan S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010;10:45
43. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-8
44. Dublin S, Walker RL, Jackson ML, et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based casecontrol study. Pharmacoepidemiol Drug Saf 2010;19:792-802
45. Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl 1985;111:7-16
46. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987;28:96-107
47. Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut 1967;8:574-81
48. Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed) 1984;289:717-19
49. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-6
50. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997;8:571-4
51. Neal KR, Scott HM, Slack RC, et al. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996;312:414-15
52. Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008;136:1225-34
53. Neal KR, Briji SO, Slack RC, et al. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ 1994;308:176
54. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007;5:1418-23
55. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, et al. Risk factors for salmonella enteritidis and typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in enteritidis and sandboxes in typhimurium infections. Epidemiol Infect 2006;134:617-26
56. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56
57. Francois M, Levy-Bohbot N, Caron J, et al. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) 2008;69:446-8
58. Ainley CC, Clarke DG, Timothy AR, et al. Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut 1986;27:337-8
59. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003;51:1339-50
60. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-5
61. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56
62. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009;104(Suppl 2):S10-16
63. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006;43:1272-6
64. Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008;62:388-96
65. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90
66. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-6
67. Carr CJ, Shangraw RF. Nutritional and pharmaceutical aspects of calcium supplementation. Am Pharm 1987;NS27:49-50.54-47
68. Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 1998;44:473-81
69. Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut 1985;26:252-7
70. Goerss JB, Kim CH, Atkinson EJ, et al. Risk of fractures in patients with pernicious anemia. J Bone Miner Res 1992;7:573-9
71. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995;14:364-8
72. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-81
73. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73:640-7
74. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9
75. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012;107:1361-9
76. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
77. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83
78. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9
79. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101
80. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990;19:141-53
81. Metz DC, Pilmer BL, Han C, et al. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 2011;106:1953-60
82. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997;92:1858-60
83. Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998;110:615-21
84. Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992;157:287-8
85. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-8
86. Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology 1993;105:1590-1
87. Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 2001;116:716-20
88. Jalving M, Koornstra JJ, Boersma-van Ek W, et al. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol 2003;38:916-22
89. Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol 2002;97:298-301
90. Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer 1994;74:556-64
91. Rubin CE. Are there three types of Helicobacter pylori gastritis? Gastroenterology 1997;112:2108-10
92. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22
93. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117:319-26
94. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009;122:896-903
95. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006;55:1217-21
96. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81
97. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
98. Robinson M. Current perspectives on hypergastrinemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999;13:5-10
99. Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68
100. Watson SA, Durrant LG, Crosbie JD, et al. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer 1989;43:692-6
101. Renga M, Brandi G, Paganelli GM, et al. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut 1997;41:330-2
102. Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998;115(2):275-80
103. Singh M, Dhindsa G, Friedland S, Triadafilopoulos G. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther 2007;26:1051-61
104. Yang YX, Hennessy S, Propert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007;133:748-54
105. Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007;133:755-60
106. van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008;103:966-73
107. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-51
108. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
109. Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1- year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013;173:518-23